newsfilter
← Latest News
GlobeNewswire·

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764

AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe and well tolerated